Project Grant R21AG091405
Award Date 9/3/26
Completion Date 8/31/28
Dollars Obligated $444K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- The National Institute on Aging awarded Duke University $647,811 on September 1, 2026, under the Aging Research program (CFDA 93.866) to define the role of lipocalin-2 in postoperative delirium. The research investigates the molecular mechanisms underlying postoperative delirium, a neurologic disorder with significant morbidity, prolonged hospitalization, and increased risk of Alzheimer's disease and related dementias. The project uses a postoperative delirium mouse model to characterize how...
- The National Institute on Aging awarded $1,161,596 to the University of Texas Health Science Center at Houston on August 1, 2026, under the Aging Research program (CFDA 93.866) to identify biomarkers and mechanisms underlying perioperative neurocognitive disorders (PND), including postoperative delirium, delayed neurocognitive recovery, and postoperative neurocognitive disorders that increase morbidity, mortality, and long-term dementia risk. The research investigates whether non-brain-derived...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $761,496 on June 15, 2026, to investigate epigenetic mechanisms linking delirium and cognitive decline under the Aging Research program (CFDA 93.866). The recipient will test the hypothesis that epigenetic risk, measured by DNA methylation, identifies individuals with a vulnerable brain predisposed to delirium, cognitive decline, and Alzheimer's disease and Alzheimer's disease-related dementias in the setting of...
- The National Institute on Aging, under the Department of Health and Human Services, awarded Duke University $627,830 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop a portable diagnostic system for Alzheimer's disease detection using circulating microRNA biomarkers. Duke's project, titled ADMIRE (Alzheimer's Detection via miRNA Evaluation), integrates two technologies: an amplification-free microRNA biosensing modality called the Inverse Molecular Sentinel and a...
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded Weill Medical College of Cornell University $172,260 on July 1, 2026, under the Aging Research program (CFDA 93.866) to characterize the relationship between electroencephalographic burst-suppression and postoperative delirium in the context of corticothalamic function. The recipient will investigate biomarkers for postoperative delirium, a neurocognitive disturbance...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $691,683 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the glymphatic system's role in perioperative neurocognitive disorder. The research characterizes how anesthesia and surgery impair glymphatic function—the brain's perivascular clearance pathway for neurotoxic proteins including beta-amyloid and phosphorylated tau—particularly in aging and Alzheimer's...
- The National Institute on Aging awarded North Carolina Central University $673,720 on September 4, 2026, under the Aging Research program (CFDA 93.866) to develop fluid biomarkers for diagnosing limbic-predominant age-related TDP-43 encephalopathy (LATE) and differentiating LATE from Alzheimer's disease dementia. The project will develop TDP-43 seed amplification assay and tau-SAA as diagnostic tests for LATE, characterize the effects of co-existing TDP-43 pathology on tau pathology across...
- The National Institute on Aging awarded the University of Florida $182,570 on July 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a prospective cohort study validating diffuse optical tomography (DOT) as a portable neuroimaging biomarker for mapping brain function in delirium and post-delirium Alzheimer's disease and related dementias. The award supports research examining whether DOT can identify impaired cerebral oxygenation and functional dysconnectivity in the...